R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Yana G. Najjar,Kristina Navrazhina,Fei Ding,Roma Bhatia,Katy K. Tsai,Kelly Abbate,Barbara Durden,Zeynep Eroglu,Shailender Bhatia,Song Park,Akansha Chowdhary,Sunandana Chandra,Jonathan Kennedy,Igor Puzanov,Marc S. Ernstoff,Pankit Vachhani,Joseph J. Drabick,Arun D. Singh,Tan Xu,Jessica Yang,Richard D. Carvajal,Daniel K. Manson,John M. Kirkwood,Justine V. Cohen,Ryan J. Sullivan,Douglas B. Johnson,Pauline Funchain,Alexander N. Shoushtari +27 more
TL;DR: Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM.
Journal ArticleDOI
A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT
Richard D. Carvajal,Paul B. Chapman,Jedd D. Wolchok,Lauren M. Cane,Jerrold B. Teitcher,Jose Lutzky,Anna C. Pavlick,Boris C. Bastian,C. R. Antonescu,Gary K. Schwartz +9 more
TL;DR: While IM has limited activity in a non-selected melanoma pt population, a substantial proportion of melanomas harboring KIT mut or amp appear to respond and it may be possible to identify appropriate pts prospectively for treatment with IM.
Journal ArticleDOI
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz,Richard D. Carvajal,Rachel Midgley,Scott J. Rodig,Paul K. Stockman,O. Ataman,David Wilson,Shampa Das,Geoffrey I. Shapiro +8 more
TL;DR: In this article, the maximum tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase, was determined.
Journal ArticleDOI
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
Archie N. Tse,David S. Klimstra,Mithat Gonen,Manish A. Shah,Tahir Sheikh,Rachel P. Sikorski,Richard D. Carvajal,Janet Mui,Caroll Tipian,Eileen M. O'Reilly,Ki Y. Chung,Robert G. Maki,Robert A. Lefkowitz,Karen T. Brown,Katia Manova-Todorova,Nian Wu,Merrill J. Egorin,David P. Kelsen,Gary K. Schwartz +18 more
TL;DR: The combination of irinotecan and the Hsp90 inhibitor 17AAG can be given to patients with acceptable toxicity and could be shown in tumor biopsy samples obtained at the maximum tolerated dose (MTD).
Journal ArticleDOI
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.
David P. Al-Adra,Laura L. Hammel,John P. Roberts,E. Steve Woodle,Deborah Levine,Didier A. Mandelbrot,Elizabeth C. Verna,Jayme E. Locke,Jonathan D'Cunha,Maryjane Farr,Deirdre Sawinski,Piyush K. Agarwal,Jennifer K. Plichta,Sandhya Pruthi,Deborah Farr,Richard D. Carvajal,John Walker,Fiona Zwald,Thomas M. Habermann,Morie A. Gertz,Philip J. Bierman,Don S. Dizon,Carrie L. Langstraat,Talal Al-Qaoud,Scott E. Eggener,John Richgels,George J. Chang,Cristina B. Geltzeiler,Gonzalo Sapisochin,Rocco Ricciardi,Alexander S. Krupnick,Cassie C. Kennedy,Nisha Mohindra,David P. Foley,Kymberly D. Watt +34 more
TL;DR: This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers.